Neurimmune-led research consortium receives Target ALS discovery grant

Target ALS has awarded Neurimmune's project focused on developing human antibodies to target dipeptide-repeat protein toxicity in C9ORF72 disease. The research consortium led by Fabio Montrasio (Neurimmune) in collaboration with Laura Ranum (University of Florida), Magdalini Polymenidou (University of Zurich) and Clotilde Lagier-Tourenne (Massachusetts General Hospital) won additional target discovery and development funding. The consortium is one out of six research consortia distinguished for working towards the development of ground-breaking therapeutic approaches to treating ALS.